Last reviewed · How we verify
Targeting CD276 CAR T cells
At a glance
| Generic name | Targeting CD276 CAR T cells |
|---|---|
| Sponsor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- B7-H3.CD28Z.CART in CNS Neoplasms (PHASE1)
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer (PHASE1, PHASE2)
- Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor (EARLY_PHASE1)
- TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia (NA)
- CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors (NA)
- 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma (PHASE1, PHASE2)
- Combination Immunotherapy Targeting Sarcomas (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |